Month: March 2023

SCYNEXIS announced it has signed an exclusive agreement with GSK to commercialize and further develop BREXAFEMME® (ibrexafungerp tablets) for all indications. GSK will make an upfront payment to SCYNEXIS of $90 million, as well as potential future milestones and tiered royalties.SCYNEXIS retains rights to all other assets in the novel “fungerp” antifungal class, including SCY-247, currently in preclinical investigation, with GSK having a right of first negotiation to these preclinical and discovery stage compounds.Enrollment is complete in the FURI and CARES Phase 3 trials of ibrexafungerp to fight serious drug-resistant refractory invasive fungal infections and in the SCYNERGIA Phase 2 trial of ibrexafungerp in invasive aspergillosis.SCYNEXIS ended Q4 2022 with cash, cash equivalents and short-term investments of $73.5 million,...

ULAANBAATAR, Mongolia, March 31, 2023 (GLOBE NEWSWIRE) — Steppe Gold Ltd. (TSX: STGO) (OTCQX: STPGF) (FSE: 2J9) (“Steppe Gold” or the “Company”) is pleased to announce its financial results for the year ended December 31, 2022. HIGHLIGHTS Year Ended December 31, 2022 Highlights (all figures in US$000’s unless stated otherwise and except for per unit amounts which are in US$)Revenue for the year ended December 31, 2022, was $62,366 (December 31, 2021 $24,050) on sales of 33,681 gold ounces (December 31, 2021: 12,899 gold ounces) and 38,740 silver ounces (December 31, 2021: 28,622 silver ounces) with average realized prices per ounce of $1,818 and $20 respectively (December 31, 2021: $1,837 and $24). Operating income from mine operations, before depreciation and depletion was $35,028 (December 31, 2021: $12,435). Adjusted EBITDA...

Revenues for 2022 totaled a record of $18.8 million, up 83% compared to 2021 “Our impressive growth, ongoing exponential decrease in burn rate, a trend that strengthened significantly into the first quarter of 2023, and cash balance combined with additional available financial resources of $2.7 million, allow us to continue support of our growth and business”  TEL AVIV, Israel, March 31, 2023 (GLOBE NEWSWIRE) — Alarum Technologies Ltd. (Nasdaq, TASE: ALAR) (“Alarum” or the “Company”), a global provider of enterprise and consumers internet access solutions, today announced record financial results for the three months and year ended December 31, 2022.  Key highlights for the three months and year ended December 31, 2022:Revenues for the three months ended December 31, 2022, reached a record high of $5.2 million, an...

$17.5 Million in Cash and Marketable Securities as of December 31, 2022; Expected to Support Operations Into Second Half of 2024 SOLANA BEACH, Calif., March 31, 2023 (GLOBE NEWSWIRE) — Artelo Biosciences, Inc. (Nasdaq:ARTL), a clinical-stage pharmaceutical company focused on modulating lipid-signaling pathways to develop treatments for people living with cancer, pain, and neurological conditions, today reported financial and operating results for the fiscal year ended December 31, 2022 and provided a business update. “We achieved meaningful clinical progress throughout 2022,” stated Gregory D. Gorgas, President and Chief Executive Officer of Artelo Biosciences. “Importantly, we completed enrollment of the first three cohorts in our Cancer Appetite Recovery Study (CAReS), evaluating ART27.13 for the treatment of cancer-related anorexia...

Achieved record revenue of $36.2 million, representing 21% increase over the year 2021 Company to host conference call and webcast today, March 31, 2023, at 8:30 AM ET HORSHAM, Pa., March 31, 2023 (GLOBE NEWSWIRE) — STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, today announced financial results for the fourth quarter and full year ended December 31, 2022. Fourth Quarter 2022 and Recent Business Highlights:Revenue in the fourth quarter of 2022 was a record $10.6 million, an increase of 17% over the fourth quarter of 2021Global recurring revenue was $6.5 million Gross domestic recurring billings were $5.8 millionRevenue for the full year 2022 was $36.2 million, a 21% increase over...

OREM, Utah, March 31, 2023 (GLOBE NEWSWIRE) — Reflect Scientific Inc (OTCQB: RSCF), a provider of ultra-low temperature freezers and chillers for the biotech, pharmaceutical, and cannabis industries, today announced its financial results for the year ended December 31, 2022. Revenue for the year decreased by 27.5% to $2,041,297, compared to $2,814,670 in 2021, primarily due to a significant decrease in freezer and chiller sales during the third quarter and ongoing supply chain delays with manufacturers. However, the cost of goods sold decreased by 7.0% to $822,147, resulting in a gross profit margin of 59.7% for the year, compared to 68.6% in 2021. Reflect Scientific’s net income for the year was $89,396, compared to $939,065 in 2021. Management is actively seeking opportunities to increase sales, improve gross margins and...

• 2022 Product Revenue Increased to $54.1 Million, Up 13% over 2021 • Global End User Demand Increased 22% over 2021 to 9,266 Units • Strengthened Balance Sheet, Repurchased Stock and Extended Term Loan Facility ATLANTA, March 31, 2023 (GLOBE NEWSWIRE) — Alimera Sciences, Inc. (Nasdaq: ALIM) a global pharmaceutical company whose mission is to be invaluable to patients, physicians, and partners concerned with retinal health and maintaining better vision longer, today announced financial results for 2022. Alimera will host a conference call today at 9:00 a.m. ET to discuss these results. Details for the call can be found below. “We have begun to see positive results from the growth initiatives we commenced over a year ago, with 22% global end user demand growth year over year in ILUVIEN sales driven by our U.S. segment growth of...

— Completed business combination with FLAC and closed concurrent, oversubscribed approximately $235 million PIPE, led by Frazier Healthcare Partners and Bain Capital Life Sciences, extending expected cash runway through 2026 — — Announced positive topline results from ROSE2 Phase 2 clinical trial evaluating obicetrapib in combination with ezetimibe as an adjunct to high-intensity statin therapy; plan to present full data at NLA Scientific Sessions in June 2023 — — Initiated Phase 2 dose-finding study evaluating obicetrapib in Japanese patients; expect to report topline results in 2H 2023 — — Pivotal Phase 3 BROOKLN, BROADWAY and PREVAIL trials on-track — NAARDEN, The Netherlands and MIAMI, March 31, 2023 (GLOBE NEWSWIRE) — NewAmsterdam Pharma Company N.V. (Nasdaq: NAMS or “NewAmsterdam”...